Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency
<jats:label>0</jats:label>Abstract In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2 including among patients with innate or acquired immunodeficiency. However, the association between COVID-19-associated mortality in patients with immunodeficiency and therapeutic use of convalescent plasma is unknown. We review clinical features and treatment protocols of COVID-19 patients with immunodeficiency after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. These insights provide evidence for the need to develop a clear treatment protocol for COVID-19 patients with immunodeficiency and support the efficacy of convalescent plasma in patients with primary or secondary immunodeficiency..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 12. Okt. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Senefeld, Jonathon W. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2020.11.08.20224790 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019312741 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019312741 | ||
| 003 | DE-627 | ||
| 005 | 20231205150434.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201111s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.11.08.20224790 |2 doi | |
| 035 | |a (DE-627)XBI019312741 | ||
| 035 | |a (biorXiv)10.1101/2020.11.08.20224790 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Senefeld, Jonathon W. |e verfasserin |0 (orcid)0000-0001-8116-3538 |4 aut | |
| 245 | 1 | 0 | |a Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a <jats:label>0</jats:label>Abstract In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2 including among patients with innate or acquired immunodeficiency. However, the association between COVID-19-associated mortality in patients with immunodeficiency and therapeutic use of convalescent plasma is unknown. We review clinical features and treatment protocols of COVID-19 patients with immunodeficiency after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. These insights provide evidence for the need to develop a clear treatment protocol for COVID-19 patients with immunodeficiency and support the efficacy of convalescent plasma in patients with primary or secondary immunodeficiency. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Klassen, Stephen A. |0 (orcid)0000-0002-4560-8728 |4 aut | |
| 700 | 1 | |a Ford, Shane K. |0 (orcid)0000-0003-2776-9023 |4 aut | |
| 700 | 1 | |a Wiggins, Chad C. |0 (orcid)0000-0002-6458-0142 |4 aut | |
| 700 | 1 | |a Bostrom, Bruce C. |0 (orcid)0000-0001-7974-1271 |4 aut | |
| 700 | 1 | |a Thompson, Michael A. |4 aut | |
| 700 | 1 | |a Baker, Sarah E. |0 (orcid)0000-0001-9647-7660 |4 aut | |
| 700 | 1 | |a Nicholson, Wayne T. |0 (orcid)0000-0002-3418-4253 |4 aut | |
| 700 | 1 | |a Johnson, Patrick W. |0 (orcid)0000-0001-8365-1375 |4 aut | |
| 700 | 1 | |a Carter, Rickey E. |0 (orcid)0000-0002-0818-273X |4 aut | |
| 700 | 1 | |a Henderson, Jeffrey P. |0 (orcid)0000-0003-1755-3202 |4 aut | |
| 700 | 1 | |a Hartman, William R. |0 (orcid)0000-0003-2118-7591 |4 aut | |
| 700 | 1 | |a Pirofski, Liise-anne |4 aut | |
| 700 | 1 | |a Wright, R. Scott |4 aut | |
| 700 | 1 | |a Fairweather, DeLisa |0 (orcid)0000-0003-3093-1810 |4 aut | |
| 700 | 1 | |a Bruno, Katelyn A. |0 (orcid)0000-0001-8980-6059 |4 aut | |
| 700 | 1 | |a Paneth, Nigel S. |0 (orcid)0000-0002-0151-966X |4 aut | |
| 700 | 1 | |a Casadevall, Arturo |0 (orcid)0000-0002-9402-9167 |4 aut | |
| 700 | 1 | |a Joyner, Michael J. |0 (orcid)0000-0002-7135-7643 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 12. Okt. |
| 773 | 1 | 8 | |g year:2023 |g day:12 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.11.08.20224790 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 12 |c 10 | ||